<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01421862</url>
  </required_header>
  <id_info>
    <org_study_id>FHCRC-9140</org_study_id>
    <secondary_id>CDR0000709269</secondary_id>
    <nct_id>NCT01421862</nct_id>
  </id_info>
  <brief_title>Biomarkers in Samples From Adult Patients With Acute Myeloid Leukemia Who Failed Existing Standard-of-Care Treatment</brief_title>
  <official_title>The Genetics of &quot;Non-Response&quot; in Adult AML</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of bone marrow and blood from patients with cancer who failed
      treatment may help doctors learn more about changes that occur in DNA and identify biomarkers
      related to cancer resistance. It may also help doctors find better ways to treat cancer.

      PURPOSE: This research trial studies biomarkers in samples from adult patients with acute
      myeloid leukemia who failed standard-of-care treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Define a &quot;non-response&quot; signature that will help up-front identification of cases of
           intermediate-risk acute myeloid leukemia (AML) destined to fail existing
           standard-of-care therapy.

        -  Identify biological pathways in the &quot;non-response&quot; group that can provide targets for
           novel therapeutics.

      OUTLINE: DNA and RNA extracted from cryopreserved bone marrow cells and/or blood cells are
      analyzed for mutations and gene expression signatures (genome-wide methylation, mRNA and
      miRNA expression, and single nucleotide polymorphism (SNP) analysis) by microarray assays.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2011</start_date>
  <primary_completion_date type="Anticipated">October 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Genetic signature predictive of progression and drug resistance in AML</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identification of biological pathways in non-responder AML patients</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>DNA methylation analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>RNA analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>microarray analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>mutation analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>nucleic acid sequencing</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Samples from previously untreated non-M3 acute myeloid leukemia (AML)

          -  Normal karyotype (NK) intermediate-risk disease

          -  Two or more vials of cryopreserved pretreatment bone marrow cells and/or two or more
             vials of cryopreserved pretreatment blood cells available from the Intergroup AML
             Repository

          -  Blast count â‰¥ 60%

          -  Eligible and evaluable for the patient's clinical trial, and did not have fatal
             induction toxicity

          -  Response to protocol induction chemotherapy:

               -  Non-response: AML with failure to achieve a complete remission (CR) after
                  induction chemotherapy (&quot;7 &amp; 3&quot;-based therapy using cytatabine and/or
                  daunorobicin hydrochloride (DNR) OR idarubicin and/or DNR

               -  Responders: continued complete remission (CCR) &gt; 2 years

        PATIENT CHARACTERISTICS:

          -  Not specified

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerry Radich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2011</study_first_submitted>
  <study_first_submitted_qc>August 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2011</study_first_posted>
  <last_update_submitted>July 9, 2013</last_update_submitted>
  <last_update_submitted_qc>July 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2013</last_update_posted>
  <responsible_party>
    <name_title>Jerry Radich</name_title>
    <organization>Fred Hutchinson Cancer Research Center</organization>
  </responsible_party>
  <keyword>adult acute basophilic leukemia</keyword>
  <keyword>adult acute eosinophilic leukemia</keyword>
  <keyword>adult erythroleukemia (M6a)</keyword>
  <keyword>adult pure erythroid leukemia (M6b)</keyword>
  <keyword>adult acute minimally differentiated myeloid leukemia (M0)</keyword>
  <keyword>adult acute monoblastic leukemia (M5a)</keyword>
  <keyword>adult acute monocytic leukemia (M5b)</keyword>
  <keyword>adult acute myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>adult acute myelomonocytic leukemia (M4)</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with del(5q)</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>adult acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>adult acute megakaryoblastic leukemia (M7)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

